Dogwood Therapeutics Q2 FY26 net loss widens to $11.5 million

Reuters2026/08/13 12:32

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Dogwood Therapeutics posted a Q2 net loss attributable to common stockholders of $11.5 million, or $0.34 a share.
R&D expense rose to $3.25 million from $2.57 million a year earlier, due to higher Halneuron Phase 2b CINP study costs.
G&A expense increased to $1.63 million from $1.35 million, on higher salaries and related personnel costs.
Booked a $6.7 million net non-cash impairment charge tied to goodwill and IPR&D, including a $9.2 million IPR&D impairment.
Cash totaled $9.61 million; Halneuron Phase 2b CINP trial had 217 patients enrolled, with top-line results expected in fall 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608130830PRIMZONEFULLFEED9809209) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Dogwood Therapeutics Q2 FY26 net loss widens to $11.5 million

You may also like

Crypto prices